The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-α inhibitors versus phototherapy: An observational cohort study
Journal of the American Academy of Dermatology. 2018 Jul;79(1):60-68
BACKGROUND:
Psoriasis is a risk factor for cardiovascular events.
OBJECTIVE:
To assess the risk of major cardiovascular events and the effect of cumulative treatment exposure on cardiovascular event riskin patients with psoriasis treated with tumor necrosis factor-α inhibitors (TNFis) versus phototherapy.
METHODS:
Adult patients with psoriasis were selected from a large US administrative claims database (from the first quarter of 2000 through the third quarter of 2014) and classified in 2 mutually exclusive cohorts based on whether they were treated with TNFis or phototherapy. Cardiovascular event risk was compared between cohorts using multivariate Cox proportional hazards models. Cumulative exposure was defined based on treatment persistence.
RESULTS:
A total of 11,410 TNFi and 12,433 phototherapy patients (psoralen plus ultraviolet A light phototherapy, n = 1117; ultraviolet B light phototherapy, n = 11,316) were included in this study. TNFi patients had a lower risk of cardiovascular events compared to phototherapypatients (adjusted hazard ratio 0.77, P < .05). the risk reduction associated with 6 months of cumulative exposure was 11.2% larger for patients treated with tnfis compared to phototherapy (p >< .05).>
LIMITATIONS:
Information on psoriasis severity and mortality was limited/not available.
CONCLUSIONS:
Patients with psoriasis who were treated with TNFis exhibited a lower cardiovascular event risk than patients treated with phototherapy. Cumulative exposure to TNFis was associated with an incremental cardiovascular risk reduction compared to phototherapy.